Chiron Seeking To Bump Up Buyout Bid? Directors Reject Novartis’ Offer
This article was originally published in The Pink Sheet Daily
Executive Summary
A $4.5 bil. cash offer from Novartis for an outstanding 57.8% stake in Chiron is “inadequate,” according to Chiron’s independent directors.